{"transactions":[{"id":334164,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-03T20:14:18.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":3142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":3142,"derivative":{"exercise_price":399.71,"expiration_date":"2034-04-30","underlying":"Common Stock","underlying_shares":3142},"source":{"system":"sec-edgar","filing":"0000875320-24-000123","document":"wk-form4_1714767244.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000123/wk-form4_1714767244.xml","form_type":"4"}},{"id":346633,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-14T20:09:17.000Z","date":"2023-08-10","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":10000,"derivative":{"exercise_price":127.54,"expiration_date":"2025-05-31","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-23-018113","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924323018113/doc4.xml","form_type":"4"}},{"id":346632,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-14T20:09:17.000Z","date":"2023-08-10","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":350,"value":3500000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Kearney's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023."}],"balance_after":6536,"source":{"system":"sec-edgar","filing":"0000899243-23-018113","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924323018113/doc4.xml","form_type":"4"}},{"id":346631,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-14T20:09:17.000Z","date":"2023-08-10","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":127.54,"value":1275400.0,"ownership":{"direct":true},"balance_after":16536,"source":{"system":"sec-edgar","filing":"0000899243-23-018113","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924323018113/doc4.xml","form_type":"4"}},{"id":349494,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-03T20:55:39.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":3481,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":3481,"derivative":{"exercise_price":342.73,"expiration_date":"2033-04-30","underlying":"Common Stock","underlying_shares":3481},"source":{"system":"sec-edgar","filing":"0001209191-23-027028","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123027028/doc4.xml","form_type":"4"}},{"id":361985,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-03T21:41:51.000Z","date":"2022-05-01","kind":"grant","acquired":true,"shares":2231,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2231,"derivative":{"exercise_price":276.17,"exercise_date":"2022-05-01","expiration_date":"2032-04-30","underlying":"Common Stock","underlying_shares":2231},"source":{"system":"sec-edgar","filing":"0000899243-22-016384","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322016384/doc4.xml","form_type":"4"}},{"id":361984,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-03T21:41:51.000Z","date":"2022-05-01","kind":"grant","acquired":true,"shares":725,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date."}],"balance_after":6536,"source":{"system":"sec-edgar","filing":"0000899243-22-016384","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322016384/doc4.xml","form_type":"4"}},{"id":2500529,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:08:11.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":3222,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":115.53,"underlying":"Common Stock","underlying_shares":3222},"source":{"system":"sec-edgar","filing":"0001104659-21-142274","document":"tm2133601-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000110465921142274/tm2133601-8_4seq1.xml","form_type":"4"}},{"id":2500528,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:08:11.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":8185,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":52.99,"underlying":"Common Stock","underlying_shares":8185},"source":{"system":"sec-edgar","filing":"0001104659-21-142274","document":"tm2133601-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000110465921142274/tm2133601-8_4seq1.xml","form_type":"4"}},{"id":2500527,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:08:11.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":41.64,"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-21-142274","document":"tm2133601-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000110465921142274/tm2133601-8_4seq1.xml","form_type":"4"}},{"id":2500526,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:08:11.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":4665,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":41.2,"underlying":"Common Stock","underlying_shares":4665},"source":{"system":"sec-edgar","filing":"0001104659-21-142274","document":"tm2133601-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000110465921142274/tm2133601-8_4seq1.xml","form_type":"4"}},{"id":2500525,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:08:11.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":40.61,"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-21-142274","document":"tm2133601-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000110465921142274/tm2133601-8_4seq1.xml","form_type":"4"}},{"id":2500524,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-22T09:08:11.000Z","date":"2021-11-19","kind":"other","acquired":false,"shares":6749,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. (\"Parent\"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 19, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. (\"Parent\"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 19, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. (\"Parent\"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 19, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-21-142274","document":"tm2133601-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000110465921142274/tm2133601-8_4seq1.xml","form_type":"4"}},{"id":376078,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-04T20:12:14.000Z","date":"2021-05-01","kind":"grant","acquired":true,"shares":6067,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":6067,"derivative":{"exercise_price":217.2,"expiration_date":"2031-04-30","underlying":"Common Stock","underlying_shares":6067},"source":{"system":"sec-edgar","filing":"0001209191-21-029850","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121029850/doc4.xml","form_type":"4"}},{"id":2885193,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-02-02T18:41:38.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":3222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date."}],"balance_after":3222,"derivative":{"exercise_price":115.53,"expiration_date":"2031-01-29","underlying":"Common Stock","underlying_shares":3222},"source":{"system":"sec-edgar","filing":"0001179110-21-001110","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000117911021001110/edgar.xml","form_type":"4"}},{"id":2885192,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-02T18:41:38.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":1622,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6749,"source":{"system":"sec-edgar","filing":"0001179110-21-001110","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000117911021001110/edgar.xml","form_type":"4"}},{"id":3008061,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2020-10-13T19:14:30.000Z","date":"2020-10-12","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares of common stock underlying this stock option award vested in full on the one year anniversary of the grant date."}],"balance_after":0,"derivative":{"exercise_price":30.17,"expiration_date":"2027-03-02","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001179110-20-010439","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000117911020010439/edgar.xml","form_type":"4"}},{"id":3008060,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2020-10-13T19:14:30.000Z","date":"2020-10-12","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares of common stock underlying this stock option award vested in full on the one year anniversary of the grant date."}],"balance_after":0,"derivative":{"exercise_price":27.97,"expiration_date":"2026-03-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001179110-20-010439","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000117911020010439/edgar.xml","form_type":"4"}},{"id":3008059,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2020-10-13T19:14:30.000Z","date":"2020-10-12","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of common stock underlying this stock option award vested in equal quarterly installments over the first three years after the grant date."}],"balance_after":0,"derivative":{"exercise_price":28.37,"expiration_date":"2024-07-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001179110-20-010439","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000117911020010439/edgar.xml","form_type":"4"}},{"id":3008058,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-13T19:14:30.000Z","date":"2020-10-12","kind":"sale","acquired":false,"shares":913,"price":120.57,"value":110080.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.50 to $120.70 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4."}],"balance_after":5127,"source":{"system":"sec-edgar","filing":"0001179110-20-010439","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000117911020010439/edgar.xml","form_type":"4"}},{"id":3008057,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-13T19:14:30.000Z","date":"2020-10-12","kind":"sale","acquired":false,"shares":16210,"price":119.78,"value":1941633.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.50 to $120.48 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4."}],"balance_after":6040,"source":{"system":"sec-edgar","filing":"0001179110-20-010439","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000117911020010439/edgar.xml","form_type":"4"}},{"id":3008056,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-13T19:14:30.000Z","date":"2020-10-12","kind":"sale","acquired":false,"shares":18177,"price":119.11,"value":2165062.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.50 to $119.49 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":22250,"source":{"system":"sec-edgar","filing":"0001179110-20-010439","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000117911020010439/edgar.xml","form_type":"4"}},{"id":3008055,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-13T19:14:30.000Z","date":"2020-10-12","kind":"sale","acquired":false,"shares":2200,"price":117.82,"value":259204.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.29 to $118.08 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":40427,"source":{"system":"sec-edgar","filing":"0001179110-20-010439","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000117911020010439/edgar.xml","form_type":"4"}},{"id":3008054,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-13T19:14:30.000Z","date":"2020-10-12","kind":"exercise","acquired":true,"shares":7500,"price":30.17,"value":226275.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":42627,"source":{"system":"sec-edgar","filing":"0001179110-20-010439","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000117911020010439/edgar.xml","form_type":"4"}},{"id":3008053,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-13T19:14:30.000Z","date":"2020-10-12","kind":"exercise","acquired":true,"shares":10000,"price":27.97,"value":279700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":35127,"source":{"system":"sec-edgar","filing":"0001179110-20-010439","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000117911020010439/edgar.xml","form_type":"4"}},{"id":3008052,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-13T19:14:30.000Z","date":"2020-10-12","kind":"exercise","acquired":true,"shares":20000,"price":28.37,"value":567400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":25127,"source":{"system":"sec-edgar","filing":"0001179110-20-010439","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000117911020010439/edgar.xml","form_type":"4"}},{"id":389774,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-03T20:29:39.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":4527,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":4527,"derivative":{"exercise_price":286.27,"expiration_date":"2030-05-31","underlying":"Common Stock","underlying_shares":4527},"source":{"system":"sec-edgar","filing":"0001209191-20-034027","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919120034027/doc4.xml","form_type":"4"}},{"id":3302840,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2020-01-24T17:45:04.000Z","date":"2020-01-22","kind":"grant","acquired":true,"shares":8185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date."}],"balance_after":8185,"derivative":{"exercise_price":52.99,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":8185},"source":{"system":"sec-edgar","filing":"0001179110-20-000777","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000117911020000777/edgar.xml","form_type":"4"}},{"id":3302839,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-24T17:45:04.000Z","date":"2020-01-22","kind":"grant","acquired":true,"shares":1377,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5127,"source":{"system":"sec-edgar","filing":"0001179110-20-000777","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000117911020000777/edgar.xml","form_type":"4"}},{"id":399324,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-11-04T21:15:46.000Z","date":"2019-11-01","kind":"exercise","acquired":false,"shares":7073,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":93.51,"expiration_date":"2026-05-31","underlying":"Common Stock","underlying_shares":7073},"source":{"system":"sec-edgar","filing":"0001209191-19-054882","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919119054882/doc4.xml","form_type":"4"}},{"id":399323,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-11-04T21:15:46.000Z","date":"2019-11-01","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":72.14,"expiration_date":"2024-05-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-19-054882","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919119054882/doc4.xml","form_type":"4"}},{"id":399322,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-11-04T21:15:46.000Z","date":"2019-11-01","kind":"exercise","acquired":false,"shares":375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":56.99,"expiration_date":"2021-05-16","underlying":"Common Stock","underlying_shares":375},"source":{"system":"sec-edgar","filing":"0001209191-19-054882","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919119054882/doc4.xml","form_type":"4"}},{"id":399321,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-11-04T21:15:46.000Z","date":"2019-11-01","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":81.54,"expiration_date":"2023-05-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-19-054882","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919119054882/doc4.xml","form_type":"4"}},{"id":399320,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-04T21:15:46.000Z","date":"2019-11-01","kind":"sale","acquired":false,"shares":7073,"price":200,"value":1414600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Kearney's company approved trading plan under Rule 10b5-1."}],"balance_after":5811,"source":{"system":"sec-edgar","filing":"0001209191-19-054882","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919119054882/doc4.xml","form_type":"4"}},{"id":399319,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-04T21:15:46.000Z","date":"2019-11-01","kind":"exercise","acquired":true,"shares":7073,"price":93.51,"value":661396.23,"ownership":{"direct":true},"balance_after":12884,"source":{"system":"sec-edgar","filing":"0001209191-19-054882","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919119054882/doc4.xml","form_type":"4"}},{"id":399318,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-04T21:15:46.000Z","date":"2019-11-01","kind":"sale","acquired":false,"shares":20000,"price":200,"value":4000000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Kearney's company approved trading plan under Rule 10b5-1."}],"balance_after":5811,"source":{"system":"sec-edgar","filing":"0001209191-19-054882","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919119054882/doc4.xml","form_type":"4"}},{"id":399317,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-04T21:15:46.000Z","date":"2019-11-01","kind":"exercise","acquired":true,"shares":20000,"price":72.14,"value":1442800.0,"ownership":{"direct":true},"balance_after":25811,"source":{"system":"sec-edgar","filing":"0001209191-19-054882","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919119054882/doc4.xml","form_type":"4"}},{"id":399316,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-04T21:15:46.000Z","date":"2019-11-01","kind":"sale","acquired":false,"shares":375,"price":200,"value":75000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Kearney's company approved trading plan under Rule 10b5-1."}],"balance_after":5811,"source":{"system":"sec-edgar","filing":"0001209191-19-054882","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919119054882/doc4.xml","form_type":"4"}},{"id":399315,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-04T21:15:46.000Z","date":"2019-11-01","kind":"exercise","acquired":true,"shares":375,"price":56.99,"value":21371.25,"ownership":{"direct":true},"balance_after":6186,"source":{"system":"sec-edgar","filing":"0001209191-19-054882","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919119054882/doc4.xml","form_type":"4"}},{"id":399314,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-04T21:15:46.000Z","date":"2019-11-01","kind":"sale","acquired":false,"shares":20000,"price":200,"value":4000000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Kearney's company approved trading plan under Rule 10b5-1."}],"balance_after":5811,"source":{"system":"sec-edgar","filing":"0001209191-19-054882","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919119054882/doc4.xml","form_type":"4"}},{"id":399313,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-04T21:15:46.000Z","date":"2019-11-01","kind":"exercise","acquired":true,"shares":20000,"price":81.54,"value":1630800.0,"ownership":{"direct":true},"balance_after":25811,"source":{"system":"sec-edgar","filing":"0001209191-19-054882","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919119054882/doc4.xml","form_type":"4"}},{"id":399312,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-04T21:15:46.000Z","date":"2019-11-01","kind":"sale","acquired":false,"shares":3159,"price":200,"value":631800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Kearney's company approved trading plan under Rule 10b5-1."}],"balance_after":5811,"source":{"system":"sec-edgar","filing":"0001209191-19-054882","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919119054882/doc4.xml","form_type":"4"}},{"id":399311,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-04T21:15:46.000Z","date":"2019-10-31","kind":"sale","acquired":false,"shares":1841,"price":200,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Kearney's company approved trading plan under Rule 10b5-1."}],"balance_after":8970,"source":{"system":"sec-edgar","filing":"0001209191-19-054882","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919119054882/doc4.xml","form_type":"4"}},{"id":402547,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-04T20:13:07.000Z","date":"2019-06-01","kind":"grant","acquired":true,"shares":2381,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date."}],"balance_after":10811,"source":{"system":"sec-edgar","filing":"0001209191-19-034230","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919119034230/doc4.xml","form_type":"4"}},{"id":3683714,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2019-01-29T17:46:16.000Z","date":"2019-01-25","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date."}],"balance_after":7500,"derivative":{"exercise_price":41.64,"expiration_date":"2029-01-25","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001179110-19-001060","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000117911019001060/edgar.xml","form_type":"4"}},{"id":3683713,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-29T17:46:16.000Z","date":"2019-01-25","kind":"grant","acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3750,"source":{"system":"sec-edgar","filing":"0001179110-19-001060","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000117911019001060/edgar.xml","form_type":"4"}},{"id":414311,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-05T20:58:54.000Z","date":"2018-06-01","kind":"grant","acquired":true,"shares":3229,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":3229,"derivative":{"exercise_price":152.74,"expiration_date":"2028-05-31","underlying":"Common Stock","underlying_shares":3229},"source":{"system":"sec-edgar","filing":"0001209191-18-035772","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118035772/doc4.xml","form_type":"4"}},{"id":414310,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-05T20:58:54.000Z","date":"2018-06-01","kind":"grant","acquired":true,"shares":1801,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date."}],"balance_after":8430,"source":{"system":"sec-edgar","filing":"0001209191-18-035772","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118035772/doc4.xml","form_type":"4"}},{"id":3932947,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-15T12:32:12.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":2905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option."}],"balance_after":0,"derivative":{"exercise_price":133.8,"expiration_date":"2028-03-13","underlying":"Common Stock","underlying_shares":2905},"source":{"system":"sec-edgar","filing":"0001209191-18-030120","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030120/doc4.xml","form_type":"4"}},{"id":3932946,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-15T12:32:12.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":2454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option."}],"balance_after":0,"derivative":{"exercise_price":69.25,"expiration_date":"2027-05-30","underlying":"Common Stock","underlying_shares":2454},"source":{"system":"sec-edgar","filing":"0001209191-18-030120","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030120/doc4.xml","form_type":"4"}},{"id":3932945,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-15T12:32:12.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":26496,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option."}],"balance_after":0,"derivative":{"exercise_price":20,"expiration_date":"2026-02-10","underlying":"Common Stock","underlying_shares":26496},"source":{"system":"sec-edgar","filing":"0001209191-18-030120","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030120/doc4.xml","form_type":"4"}},{"id":3932944,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-15T12:32:12.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":1106,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents 1,106 shares underlying Restricted Stock Units (the \"RSUs\"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-030120","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030120/doc4.xml","form_type":"4"}},{"id":3978778,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-30T17:54:23.000Z","date":"2018-03-13","kind":"grant","acquired":true,"shares":2905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable on March 13, 2019, subject to the Reporting Person's continuous service with the Issuer on such date."}],"balance_after":2905,"derivative":{"exercise_price":133.8,"expiration_date":"2028-03-13","underlying":"Common Stock","underlying_shares":2905},"source":{"system":"sec-edgar","filing":"0001209191-18-022243","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118022243/doc4.xml","form_type":"4"}},{"id":3978777,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-30T17:54:23.000Z","date":"2018-03-13","kind":"grant","acquired":true,"shares":1106,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest on March 13, 2019, subject to the Reporting Person's continuous service with the Issuer on such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest on March 13, 2019, subject to the Reporting Person's continuous service with the Issuer on such date."}],"balance_after":1106,"source":{"system":"sec-edgar","filing":"0001209191-18-022243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118022243/doc4.xml","form_type":"4"}},{"id":4014581,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2018-03-05T17:20:53.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date."}],"balance_after":7500,"derivative":{"exercise_price":40.61,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001179110-18-003504","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000117911018003504/edgar.xml","form_type":"4"}},{"id":4014580,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-05T17:20:53.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001179110-18-003504","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000117911018003504/edgar.xml","form_type":"4"}},{"id":425813,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-05T21:11:29.000Z","date":"2017-06-01","kind":"exercise","acquired":true,"shares":5295,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":5295,"derivative":{"exercise_price":125.71,"expiration_date":"2027-05-31","underlying":"Common Stock","underlying_shares":5295},"source":{"system":"sec-edgar","filing":"0001209191-17-037815","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919117037815/doc4.xml","form_type":"4"}},{"id":425812,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-05T21:11:29.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":2188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date."}],"balance_after":6629,"source":{"system":"sec-edgar","filing":"0001209191-17-037815","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919117037815/doc4.xml","form_type":"4"}},{"id":4298183,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-01T18:05:58.000Z","date":"2017-05-30","kind":"grant","acquired":true,"shares":2454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable (i) in twelve equal monthly installments beginning on June 30, 2017, or (ii) on the date of the Issuer's next annual stockholder meeting, whichever comes first, in each case subject to the Reporting Person's Continuous Service (as that term is defined in the Issuer's 2016 Equity Incentive Plan) through each such date."}],"balance_after":2454,"derivative":{"exercise_price":69.25,"expiration_date":"2027-05-30","underlying":"Common Stock","underlying_shares":2454},"source":{"system":"sec-edgar","filing":"0001209191-17-036892","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117036892/doc4.xml","form_type":"4"}},{"id":4386142,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2017-03-14T18:20:48.000Z","date":"2017-03-02","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date."}],"balance_after":7500,"derivative":{"exercise_price":30.17,"expiration_date":"2027-03-02","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001179110-17-004595","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000117911017004595/edgar.xml","form_type":"4"}},{"id":4386141,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-14T18:20:48.000Z","date":"2017-03-02","kind":"grant","acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1250,"source":{"system":"sec-edgar","filing":"0001179110-17-004595","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1289098/000117911017004595/edgar.xml","form_type":"4"}},{"id":437640,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-06-03T21:07:20.000Z","date":"2016-06-01","kind":"grant","acquired":true,"shares":7073,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":7073,"derivative":{"exercise_price":93.51,"expiration_date":"2026-05-31","underlying":"Common Stock","underlying_shares":7073},"source":{"system":"sec-edgar","filing":"0001209191-16-125710","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919116125710/doc4.xml","form_type":"4"}},{"id":437639,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-06-03T21:07:20.000Z","date":"2016-06-01","kind":"grant","acquired":true,"shares":2941,"price":0.01,"value":29.41,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests on the first anniversary of the grant date."}],"balance_after":4441,"source":{"system":"sec-edgar","filing":"0001209191-16-125710","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919116125710/doc4.xml","form_type":"4"}},{"id":450031,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2015-06-03T20:24:22.000Z","date":"2015-06-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":20000,"derivative":{"exercise_price":127.54,"exercise_date":"2015-06-01","expiration_date":"2025-05-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-15-049583","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919115049583/doc4.xml","form_type":"4"}},{"id":450579,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2015-05-21T20:16:08.000Z","date":"2015-05-19","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":375,"derivative":{"exercise_price":56.99,"expiration_date":"2021-05-16","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001209191-15-045355","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919115045355/doc4.xml","form_type":"4"}},{"id":450578,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2015-05-21T20:16:08.000Z","date":"2015-05-19","kind":"exercise","acquired":true,"shares":1500,"price":56.99,"value":85485.0,"ownership":{"direct":true},"balance_after":1500,"source":{"system":"sec-edgar","filing":"0001209191-15-045355","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919115045355/doc4.xml","form_type":"4"}},{"id":451592,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2015-04-30T00:34:30.000Z","date":"2015-04-27","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":59.55,"expiration_date":"2022-05-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-15-037170","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919115037170/doc4.xml","form_type":"4"}},{"id":451591,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2015-04-30T00:34:30.000Z","date":"2015-04-27","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":53.85,"expiration_date":"2021-05-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-15-037170","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919115037170/doc4.xml","form_type":"4"}},{"id":451590,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2015-04-30T00:34:30.000Z","date":"2015-04-27","kind":"exercise","acquired":false,"shares":28125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option vests in 16 quarterly installments from 05/17/2011."}],"balance_after":1875,"derivative":{"exercise_price":56.99,"expiration_date":"2021-05-16","underlying":"Common Stock","underlying_shares":28125},"source":{"system":"sec-edgar","filing":"0001209191-15-037170","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919115037170/doc4.xml","form_type":"4"}},{"id":451589,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2015-04-30T00:34:30.000Z","date":"2015-04-27","kind":"sale","acquired":false,"shares":2300,"price":133.63,"value":307349.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Kearney's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Kearney undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Open market sales reported on this line occurred at a weighted average price of $133.63 (range $133.36 to $134.09)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-15-037170","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919115037170/doc4.xml","form_type":"4"}},{"id":451588,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2015-04-30T00:34:30.000Z","date":"2015-04-27","kind":"sale","acquired":false,"shares":5668,"price":132.82,"value":752823.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Kearney's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Kearney undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Open market sales reported on this line occurred at a weighted average price of $132.82 (range $132.32 to $133.30)."}],"balance_after":2300,"source":{"system":"sec-edgar","filing":"0001209191-15-037170","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919115037170/doc4.xml","form_type":"4"}},{"id":451587,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2015-04-30T00:34:30.000Z","date":"2015-04-27","kind":"sale","acquired":false,"shares":3969,"price":131.76,"value":522955.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Kearney's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Kearney undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $131.76 (range $131.25 to $132.20)."}],"balance_after":7968,"source":{"system":"sec-edgar","filing":"0001209191-15-037170","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919115037170/doc4.xml","form_type":"4"}},{"id":451586,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2015-04-30T00:34:30.000Z","date":"2015-04-27","kind":"sale","acquired":false,"shares":8800,"price":130.58,"value":1149104.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Kearney's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Kearney undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $130.58 (range $130.16 to $131.14)."}],"balance_after":11937,"source":{"system":"sec-edgar","filing":"0001209191-15-037170","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919115037170/doc4.xml","form_type":"4"}},{"id":451585,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2015-04-30T00:34:30.000Z","date":"2015-04-27","kind":"sale","acquired":false,"shares":4500,"price":129.94,"value":584730.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Kearney's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Kearney undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $129.94 (range $129.16 to $130.15)."}],"balance_after":20737,"source":{"system":"sec-edgar","filing":"0001209191-15-037170","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919115037170/doc4.xml","form_type":"4"}},{"id":451584,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2015-04-30T00:34:30.000Z","date":"2015-04-27","kind":"sale","acquired":false,"shares":16295,"price":128.12,"value":2087715.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Kearney's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Kearney undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $128.12 (range $127.87 to $128.83)."}],"balance_after":25237,"source":{"system":"sec-edgar","filing":"0001209191-15-037170","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919115037170/doc4.xml","form_type":"4"}},{"id":451583,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2015-04-30T00:34:30.000Z","date":"2015-04-27","kind":"sale","acquired":false,"shares":26593,"price":127.5,"value":3390607.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Kearney's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $127.50 (range $126.87 to $127.86)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Kearney undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":41532,"source":{"system":"sec-edgar","filing":"0001209191-15-037170","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919115037170/doc4.xml","form_type":"4"}},{"id":451582,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2015-04-30T00:34:30.000Z","date":"2015-04-27","kind":"exercise","acquired":true,"shares":20000,"price":59.55,"value":1191000.0,"ownership":{"direct":true},"balance_after":68125,"source":{"system":"sec-edgar","filing":"0001209191-15-037170","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919115037170/doc4.xml","form_type":"4"}},{"id":451581,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2015-04-30T00:34:30.000Z","date":"2015-04-27","kind":"exercise","acquired":true,"shares":20000,"price":53.85,"value":1077000.0,"ownership":{"direct":true},"balance_after":48125,"source":{"system":"sec-edgar","filing":"0001209191-15-037170","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919115037170/doc4.xml","form_type":"4"}},{"id":451580,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2015-04-30T00:34:30.000Z","date":"2015-04-27","kind":"exercise","acquired":true,"shares":28125,"price":56.99,"value":1602843.75,"ownership":{"direct":true},"balance_after":28125,"source":{"system":"sec-edgar","filing":"0001209191-15-037170","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919115037170/doc4.xml","form_type":"4"}},{"id":464400,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2014-06-03T20:13:50.000Z","date":"2014-06-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":20000,"derivative":{"exercise_price":72.14,"exercise_date":"2014-06-01","expiration_date":"2024-05-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-14-038658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919114038658/doc4.xml","form_type":"4"}},{"id":476927,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2013-06-04T20:18:04.000Z","date":"2013-06-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":20000,"derivative":{"exercise_price":81.54,"exercise_date":"2013-06-01","expiration_date":"2023-05-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-13-030491","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919113030491/doc4.xml","form_type":"4"}},{"id":490852,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2012-06-01T21:05:57.000Z","date":"2012-06-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":20000,"derivative":{"exercise_price":59.55,"exercise_date":"2012-06-01","expiration_date":"2022-05-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-12-031708","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919112031708/doc4.xml","form_type":"4"}},{"id":503380,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2011-06-02T20:41:31.000Z","date":"2011-06-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":20000,"derivative":{"exercise_price":53.85,"exercise_date":"2011-06-01","expiration_date":"2021-05-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-11-032538","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919111032538/doc4.xml","form_type":"4"}},{"id":503920,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15211,"kind":"person","name":"Kearney Terrence C","position":1,"cik":"0001289098","reported_name":"Kearney Terrence C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2011-05-18T18:28:37.000Z","date":"2011-05-17","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 05/17/2011."}],"balance_after":30000,"derivative":{"exercise_price":56.99,"exercise_date":"2011-08-17","expiration_date":"2021-05-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-11-029317","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919111029317/doc4.xml","form_type":"4"}}]}